Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who have been diagnosed with a solid tumour (a type of cancer that forms a lump or mass), confirmed by laboratory testing of tissue
- People who are able to fill in questionnaires throughout the study
- People who are willing to sign a consent form agreeing to take part
- (Group I only) People who have already been receiving a specific type of cancer treatment — known as immune checkpoint inhibitors (targeting PD-1, PD-L1, or CTLA-4) or CDK inhibitors — for at least three months, where that treatment has been approved by the Italian medicines regulator (AIFA) for their specific cancer type
- (Group II only) People whose treating doctor has determined them eligible to start treatment with immune checkpoint inhibitors (targeting PD-1, PD-L1, or CTLA-4) or CDK inhibitors, where that treatment has been approved by the Italian medicines regulator (AIFA) for their specific cancer type
Who may not be able to join:
- People under 18 years of age
- People who had existing skin conditions or skin changes before starting the cancer treatments described above
- People who regularly use steroid medications on an ongoing basis
- People who have a history of psychiatric conditions, or who are currently taking antidepressant medications
- People who are unwilling to sign the consent form
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Roberto Iacovelli, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phone: +390630157373
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Quality of life in patients undergoing anti-PD1/PDL1/CTLA4 or cyclin-dependent kinase (CDK) inhibitors evaluated by EQ-5D-5L questionnaire.; Quality of life during therapy with anti-PD1/PDL1/CTLA4 or cyclin-dependent kinase (CDK) inhibitors by FACT-G scale; Quality of life during therapy with anti-PD1/PDL1/CTLA4 or cyclin-dependent kinase (CDK) inhibitors by FACT-EGFRI-18 scale. For all FACIT measures, higher scores are better than lower scores.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.